{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:08:09Z","timestamp":1789380489483,"version":"build-2803163510"},"reference-count":60,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing globally, and PDAC remains one of the deadliest malignancies, primarily because of late-stage presentation at diagnosis and limited effective therapies. KRAS mutations are present in approximately 88\u201392% of PDAC cases, making KRAS an important therapeutic target in PDAC, despite its long-standing historical classification as being \u201cundruggable.\u201d This review comprehensively examines the role of KRAS in pancreatic cancer and summarizes both indirect and direct KRAS-targeted therapeutic strategies, including downstream pathway inhibition, metabolic targeting, and emerging direct KRAS inhibitors. The ongoing clinical trials are essential for establishing the efficacy of these emerging therapies, which are poised to gradually transition into clinical practice and ultimately improve patient outcomes. A major challenge with KRAS-targeted therapy is drug resistance, which occurs through both on-target and bypass mechanisms, but emerging combination strategies targeting parallel pathways show promise. Combination approaches involving chemotherapy, immunotherapy, PRMT5 inhibition, and tumor microenvironment targeting are being actively studied to overcome resistance. Overall, KRAS-directed therapies represent a significant and evolving advancement with the potential to improve outcomes in pancreatic cancer.<\/jats:p>","DOI":"10.3390\/cancers18182961","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:34:01Z","timestamp":1789378441000},"page":"2961","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in KRAS-Targeted Therapies for Pancreatic Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Supriya","family":"Peshin","sequence":"first","affiliation":[{"name":"Division of Geriatrics, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Zahid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA 15212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9062-9761","authenticated-orcid":false,"given":"Ehab","family":"Takrori","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Hamedi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, CA 92697, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4751-0852","authenticated-orcid":false,"given":"Shafia","family":"Rahman","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center\u2014James Cancer Hospital and Solove Research Institute, Colombus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhao, H., Zhang, Y., Liu, H., Wang, Y., and Song, Z. (2024). Age-period-cohort analysis of global, regional, and national pancreatic cancer incidence, mortality, and disability-adjusted life years, 1990\u20132019. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12835-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JP9.0000000000000203","article-title":"Mortality for pancreatic cancer throughout 2003\u20132022 in the US","volume":"7","author":"Mattiuzzi","year":"2024","journal-title":"J. Pancreatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminoncol.2021.02.003","article-title":"KRAS mutation in pancreatic cancer","volume":"48","author":"Luo","year":"2021","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: Feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Takrori, E., Abdulmajid, M., Devagudi, D., Sohail, R., Sadiq, Z., Berneau, C., Shenouda, A., Adelli, R., Peshin, S., and Singal, S. (2026). Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27104413"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"151688","DOI":"10.1016\/j.bbrc.2025.151688","article-title":"Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors","volume":"760","author":"Kale","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","article-title":"Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor","volume":"172","author":"Janes","year":"2018","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-22-1304","article-title":"A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer","volume":"13","author":"Redding","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_10","unstructured":"Sesock, C. (2026, July 29). Pancreatic Cancer Diagnoses and Mortality Rates Climb; Five-Year Survival Rate for Pancreatic Cancer Stalls at 13%; Pancreatic Cancer Action Network. 16 January 2025. Available online: https:\/\/pancan.org\/press-releases\/pancreatic-cancer-deaths-continue-to-rise-five-year-survival-rate-remains-stalled-at-13-while-all-cancers-combined-reach-milestone-70\/."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bannoura, S.F., Khan, H.Y., and Azmi, A.S. (2022). KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1013902"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI59227","article-title":"Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice","volume":"122","author":"Collins","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1053\/j.gastro.2013.01.071","article-title":"Roles for KRAS in pancreatic tumor development and progression","volume":"144","author":"Logsdon","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4251\/wjgo.v15.i4.571","article-title":"Recent advances in targeted therapy for pancreatic adenocarcinoma","volume":"15","author":"Fang","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/1535-7163.MCT-13-0104","article-title":"Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma","volume":"12","author":"Mirzoeva","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.15698\/cst2018.12.166","article-title":"The role of metabolic adaptation to nutrient stress in pancreatic cancer","volume":"2","author":"Derle","year":"2018","journal-title":"Cell Stress"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a031518","DOI":"10.1101\/cshperspect.a031518","article-title":"Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers","volume":"8","author":"Aguirre","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.4251\/wjgo.v15.i11.1852","article-title":"Glutamine addiction and therapeutic strategies in pancreatic cancer","volume":"15","author":"Ren","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2159-8290.CD-17-0952","article-title":"Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and Nonautonomous Mechanisms","volume":"8","author":"Yang","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/1878-0261.70149","article-title":"The rapidly growing landscape of RAS inhibitors: From selective allele blockade to broad inhibition strategies","volume":"19","author":"Drosten","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation","volume":"41","author":"Yaeger","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/cac2.70056","article-title":"Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I\/II trials","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2303810","article-title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","volume":"389","author":"Sacher","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1158\/1078-0432.CCR-23-2098","article-title":"A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer","volume":"30","author":"Wei","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor","volume":"65","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_31","unstructured":"ClinicalTrials.gov (2026, July 29). A Phase 1\/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients with Advanced Solid Tumors Har-Boring a KRAS G12D Mutation, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05737706."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eads0239","DOI":"10.1126\/science.ads0239","article-title":"A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors","volume":"389","author":"Weller","year":"2025","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S1626","DOI":"10.1016\/j.annonc.2025.09.099","article-title":"LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","volume":"395","author":"Wainberg","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/curroncol31040150","article-title":"KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance","volume":"31","author":"Ash","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12287","DOI":"10.1021\/acs.jmedchem.5c01441","article-title":"RAS(ON) Therapies on the Horizon to Address KRAS Resistance: Highlight on a Phase III Clinical Candidate Daraxonrasib (RMC-6236)","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-4060","article-title":"Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting","volume":"26","author":"Yaeger","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic Pancreatic Cancer: ASCO Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/jnci\/djaf139","article-title":"Clinical Utility and Tissue Concordance of Circulating Tumor DNA in Pancreatic Ductal Adenocarcinoma","volume":"117","author":"Keane","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncol."},{"key":"ref_43","unstructured":"ClinicalTrials.gov (2026, July 29). Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (TNG462-C102), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06922591."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Wolpin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Sahin, I.H., Kim, H., Rubinstein, M., Verschragen, C., Hamedi, Z., and Rahman, S. (2026). Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: A systematic review. Front. Oncol., 16, Erratum in Front. Oncol. 2026, 16, 1955091. https:\/\/doi.org\/10.3389\/fonc.2026.1955091.","DOI":"10.3389\/fonc.2026.1901721"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","article-title":"A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Singhal","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_48","first-page":"1","article-title":"KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: A phase 1b\/2 trial","volume":"30","author":"Cui","year":"2026","journal-title":"Nat. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","article-title":"Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model","volume":"15","author":"Liu","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/0008-5472.CAN-25-0600","article-title":"RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non\u2013Small Cell Lung Cancer","volume":"86","author":"Solanki","year":"2025","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer","volume":"85","author":"Engstrom","year":"2025","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eado2402","DOI":"10.1126\/scitranslmed.ado2402","article-title":"Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy","volume":"16","author":"Liu","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2026.44.2_suppl.735","article-title":"Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel as first-line treatment for patients with metastatic pancreatic cancer: Phase 2a results from the ACCENT trial","volume":"44","author":"Pavlakis","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Peshin, S., Takrori, E., Kodali, N.A., Bashir, F., and Singal, S. (2025). Advances in the Management of Pancreatic Cancer: Current Strategies and Emerging Therapies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157055"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS\u2013MAPK Reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.xcrm.2020.100131","article-title":"Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1\/2 Complexes in Pancreatic Cancer","volume":"1","author":"Brown","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ma, Y., Schulz, B., Trakooljul, N., Al Ammar, M., Sekora, A., Sender, S., Hadlich, F., Zechner, D., Weiss, F.U., and Lerch, M.M. (2022). Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers, 14.","DOI":"10.3390\/cancers14184467"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2961\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:49:17Z","timestamp":1789379357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":60,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182961"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182961","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}